Today in Nature: “Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours”. A Phase 1/2a trial testing combination of visugromab and nivumab in advanced cancer patients www.nature.com/articles/s41... 🧪
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - Nature
A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can overcome resi...
www.nature.com
December 11, 2024 at 7:58 PM
Today in Nature: “Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours”. A Phase 1/2a trial testing combination of visugromab and nivumab in advanced cancer patients www.nature.com/articles/s41... 🧪
Der Krebsspezialist Catalym hat 150 Mio. USD eingeworben. Im Rahmen von vier 2025 startetenden Phase IIb-Studien sollen die Wirksamkeit, Sicherheit und das Lizenzierungspotential von Visugromab plus Nivolumab in soliden Tumoren gezeigt werden.
transkript.de/artikel/2024...
transkript.de/artikel/2024...
Catalym wirbt 150 Mio. US-Dollar ein
Der Martinsrieder Krebsspezialist Catalym GmbH hat 150 Mio. US-Dollar eingeworben. Im Rahmen von vier 2025 startetenden Phase IIb-Studien sollen die Wirksamkeit, Sicherheit und das Lizenzierungspotent...
transkript.de
July 18, 2024 at 9:37 AM
Der Krebsspezialist Catalym hat 150 Mio. USD eingeworben. Im Rahmen von vier 2025 startetenden Phase IIb-Studien sollen die Wirksamkeit, Sicherheit und das Lizenzierungspotential von Visugromab plus Nivolumab in soliden Tumoren gezeigt werden.
transkript.de/artikel/2024...
transkript.de/artikel/2024...
Results from a clinical trial of the GDF-15-blocking antibody visugromab (CTL-002) co-administered with anti-PD-1 to patients in late- or last-line treatment with relapsed or refractory cancer under ongoing prior anti-PD-1 or anti-PD-L1 treatment. #Nature
Open Access
www.nature.com/articles/s41...
Open Access
www.nature.com/articles/s41...
December 17, 2024 at 5:27 AM
Results from a clinical trial of the GDF-15-blocking antibody visugromab (CTL-002) co-administered with anti-PD-1 to patients in late- or last-line treatment with relapsed or refractory cancer under ongoing prior anti-PD-1 or anti-PD-L1 treatment. #Nature
Open Access
www.nature.com/articles/s41...
Open Access
www.nature.com/articles/s41...
Researchers at #CIMA have shown that blocking GDF-15 with visugromab restored immune response in resistant cancers. In trials, 19% of lung cancer & 18.5% of bladder cancer patients responded, achieving deep remissions after failing prior therapies. #Oncology
go.nature.com/3ORMltG
go.nature.com/3ORMltG
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - Nature
A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can overcome resi...
go.nature.com
December 12, 2024 at 12:12 PM
Researchers at #CIMA have shown that blocking GDF-15 with visugromab restored immune response in resistant cancers. In trials, 19% of lung cancer & 18.5% of bladder cancer patients responded, achieving deep remissions after failing prior therapies. #Oncology
go.nature.com/3ORMltG
go.nature.com/3ORMltG
Melero et al. report the safety and efficacy of visugromab, an antibody blocking the immunosuppressive cytokine GDF-15, in combination with anti-PD-1 in patients with advanced cancers refractory to anti-PD-1/L1 therapy. acir.org/journal-art...
January 13, 2025 at 12:30 PM
Melero et al. report the safety and efficacy of visugromab, an antibody blocking the immunosuppressive cytokine GDF-15, in combination with anti-PD-1 in patients with advanced cancers refractory to anti-PD-1/L1 therapy. acir.org/journal-art...
A GDF-15-targeting antibody visugromab reversed GDF-15-mediated resistance to anti-PD-1/PD-L1 immunotherapy, resulting in deep, long-lasting tumour regressions in some individuals
www.nature.com/articles/s41...
www.nature.com/articles/d41...
www.nature.com/articles/s41...
www.nature.com/articles/d41...
Reversing resistance to cancer immune therapy with antibodies that target GDF-15 protein
Resistance to conventional immunotherapy can be broken by a combination of agents.
www.nature.com
December 12, 2024 at 2:43 AM
A GDF-15-targeting antibody visugromab reversed GDF-15-mediated resistance to anti-PD-1/PD-L1 immunotherapy, resulting in deep, long-lasting tumour regressions in some individuals
www.nature.com/articles/s41...
www.nature.com/articles/d41...
www.nature.com/articles/s41...
www.nature.com/articles/d41...
Blockade von GDF-15 ist ein Türöffner für die #Immuntherapie. Die Universitätsmedizin Würzburg und ihr Spin-Off CatalYm veröffentlichen in Nature die Validierung von #GDF-15 als therapeutisches Zielmolekül zur Verbesserung der Immunantwo...
weiterlesen
weiterlesen
December 11, 2024 at 4:40 PM
Blockade von GDF-15 ist ein Türöffner für die #Immuntherapie. Die Universitätsmedizin Würzburg und ihr Spin-Off CatalYm veröffentlichen in Nature die Validierung von #GDF-15 als therapeutisches Zielmolekül zur Verbesserung der Immunantwo...
weiterlesen
weiterlesen
#oncology #cancercare #CatalYm #GDF15neutralisingmonoclonalantibody #visugromab #cachexia #cancerinducedcachexia #cachexiatreatment #GDFATHERtrial #preclinicalresearch #cancerpatients #humanizedmonoclonalantibody #monoclonalantibody #visugromabtreatment
pharmatimes.com/news/catalym...
pharmatimes.com/news/catalym...
CatalYm shows potential of visugromab for treating cachexia - PharmaTimes
New findings presented at international SCWD conference
pharmatimes.com
December 11, 2024 at 11:07 AM
ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm
doi.org/10.1158/2159...
doi.org/10.1158/2159...
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that ...
doi.org
February 11, 2025 at 3:09 PM
ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Munich-based CatalYm raised $150M in Series D funding led by Canaan Partners & Bioqube Ventures. Funds will accelerate Phase 2b studies of their cancer immunotherapy, visugromab. More details here: https://buff.ly/46TFfgm?utm_source=bluesky ##biotech ##startup
CatalYm Raises $150M in Series D Funding
CatalYm, a Munich, Germany-based company providing immune therapy solutions for solid tumors, raised $150M in Series D funding
buff.ly
September 17, 2024 at 7:15 AM
Neutralizing GDF-15 with visugromab turns tumors hot overcoming anti-PD(L)-1 resistance shorturl.at/tkmsH
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - PubMed
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment<sup>1</sup>. Yet, response...
shorturl.at
December 18, 2024 at 5:45 AM
Neutralizing GDF-15 with visugromab turns tumors hot overcoming anti-PD(L)-1 resistance shorturl.at/tkmsH